67.4 F
New York
Tuesday, October 20, 2020

Intec Pharma Ltd. (NASDAQ:NTEC) is Gaining Momentum on Earnings Catalyst

Must read

Renewed Optimism is Surrounding Sempra Energy (NYSE:SRE)

Sempra Energy (SRE) shares are trading at lower $127.97 and the avg recommendation for the stock is Moderate Buy, while the current analyst price...

Is Now the Time to Invest in Allison Transmission Holdings Inc. (NYSE:ALSN)?

Allison Transmission Holdings Inc. (ALSN) shares are trading at lower $41.06 and the avg recommendation for the stock is Moderate Buy, while the current...

Upwork Inc. (NASDAQ:UPWK) is Gaining Momentum on Earnings Catalyst

Upwork Inc. (UPWK) shares are trading at higher $20.68 and the avg recommendation for the stock is Moderate Buy, while the current analyst price...

DTE Energy Company (NYSE:DTE) on the Path to Ruin

DTE Energy Company (DTE) shares are trading at lower $118.17 and the avg recommendation for the stock is Moderate Buy, while the current analyst...

Intec Pharma Ltd. (NTEC) shares are trading at lower $0.24 and the avg recommendation for the stock is Hold.

To add more color to this target, the company’s high over the last year is $0.81 and the low is $0.13. Over the last 52 weeks, NTEC is down -68.56% while the S&P 500 is up 16.45%. The catalyst for this interesting swing was the company’s recent earnings report.

A Notable Earnings Report

Find out when NTEC reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.

Of course, we must look beyond the financials and question how well those numbers represent the sustainable earnings power of the business. Investors need to know how sustainable this current run. NTEC has a short ratio of 0.46 and outstanding shares of 78.96M.

Company Outlook

NTEC has seen increased volume after this news and investors are putting their support behind the value proposition. Furthermore, 10-day volume stands at 3.32 million and more growth is possible in the weeks ahead. Traders will also note the company’s earnings per share came in at -0.76. Intec Pharma Ltd. NTEC also noted assets of $21.78 million at the end of the last quarter. Investors should also keep an eye on sector updates as NTEC has historically followed its peers on positive news.

All told, Intec Pharma Ltd. NTEC has strung together solid data and demonstrated underlying fundamentals. At its current valuation, NTEC represents an interesting risk/reward case. Traders should stay tuned to see if this recent report will push the stock to test recent resistance levels.

Intec Pharma Ltd. NTEC is now commanding a market cap of 19.12M and a float of 60.13M. NTEC is increasing its credibility in this sector and that could lead to more upside down the line. Sign-up for continuing coverage on shares of NTEC stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!

Disclosure: we hold no position in NTEC, either long or short, and we have not been compensated for this article.

Latest article

Is Now the Time to Invest in SITE Centers Corp. (NYSE:SITC)?

SITE Centers Corp. (SITC) shares are trading at lower $7.19 and the avg recommendation for the stock is Moderate Buy, while the current analyst...

Anheuser-Busch InBev SA/NV (NYSE:BUD) Stock is Soaring, Here is Why

Anheuser-Busch InBev SA/NV (BUD) shares are trading at higher $55.53 and the avg recommendation for the stock is Strong Buy, while the current analyst...

Manulife Financial Corporation (NYSE:MFC) is Holding Steady

Manulife Financial Corporation (MFC) shares are trading at lower $14.02 and the avg recommendation for the stock is Strong Buy, while the current analyst...

Investor Confidence is Falling for Paychex Inc. (NASDAQ:PAYX)

Paychex Inc. (PAYX) shares are trading at lower $81.93 and the avg recommendation for the stock is Moderate Buy, while the current analyst price...

Splunk Inc. (NASDAQ:SPLK) is Gaining Momentum on Earnings Catalyst

Splunk Inc. (SPLK) shares are trading at higher $207.21 and the avg recommendation for the stock is Moderate Buy, while the current analyst price...